Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong...
Merck
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...
Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors
Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...
MSD to Acquire Ophthalmology Specialist Eyebiotech in a Deal Valued Up to USD 3 Billion
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into an agreement to acquire UK-based...
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...
Merck KGaA Launches Construction on Largest Asia-Pacific Investment with South Korean Bioprocessing Plant
Merck KGaA (ETR: MRK), the German science and technology company, has commenced construction on a...
MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...
MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First
Merck KGaA (NYSE: MRK)’s US life sciences division, MilliporeSigma, has been at the center of...
Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination
Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered...
MSD Discontinues Vibostolimab and Keytruda Combo Trial in High-Risk Melanoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced its decision to cease development of...
MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first...
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi...
MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies
Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a...
Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology
Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition...
Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates
German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...
MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...
MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...